All Search Results
News Releases
Feb 05, 2026, 11:49 ET Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Critical Care
Feb 05, 2026, 11:43 ET HelpMeSee Unveils Next-Generation MSICS Training System at SAFO to Scale Global Blindness Solutions
Manual Small Incision Cataract Surgery (MSICS) Training System at the French-Speaking African Ophthalmology Society (SAFO) conference.
More news about: HelpMeSee
Feb 05, 2026, 11:36 ET Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Critical Care
Feb 05, 2026, 10:57 ET HelpMeSee Unveils Next-Generation MSICS Training System at SAFO to Scale Global Blindness Solutions
Manual Small Incision Cataract Surgery (MSICS) Training System at the French-Speaking African Ophthalmology Society (SAFO) conference.
More news about: HelpMeSee
Feb 05, 2026, 08:00 ET Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
models, supporting broad indication potential expanding into autoimmune and inflammatory diseases, metabolic diseases, cardiovascular diseases and ophthalmology diseases. Moreover, ISM5059 is predicted to be efficacious at a low dose in humans, providing a high safety margin for future validation.Specifically,
More news about: Insilico Medicine